PTHS stock news · Pelthos Therapeutics
Get alerts for PTHS
Follow Pelthos Therapeutics (PTHS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PTHSOn Friday, 12 health care stocks saw big price changes, with CareDx and Regeneron going up and Acumen dropping.
NeutralPelthos Therapeutics shares fell, but the article gives no company news or results explaining the move. The share-price change alone does not show a change in its business outlook.
Pelthos Therapeutics is merging with Castle Creek Biosciences and creating new subsidiaries.
NeutralPelthos agreed to acquire Castle Creek's D-Fi program, with extra shares and payments tied to future goals. No trial results or value estimate are provided, leaving Pelthos's outlook unchanged.
Q2 2026 results delivered by Pelthos Therapeutics: Complete earnings call transcript available.
Good for PTHSPelthos Therapeutics reported a significant increase in net product revenue for Q2 2026, driven by strong sales of its lead product, Zelsuvmi, and strategic partnerships that enhance distribution. This positive financial performance and upcoming product launches position the company for continued growth, making it a compelling investment opportunity.
Pelthos Therapeutics Inc. disclaims reliance on earlier financial statements and associated audit reports or interim reviews (PTHS).
Bad for PTHSPelthos Therapeutics has filed a Form 8-K indicating non-reliance on its previously issued financial statements, which raises concerns about the accuracy of its financial reporting and could lead to significant market repercussions.